TOKYO, Jun 24 (Pulse News Wire) – GNI Group Ltd. (2160.T) announced that its subsidiary, Gyre Therapeutics, Inc., filed a Form S-3 registration statement with the U.S.
Securities and Exchange Commission. This filing enables future resale of shares issued to Cullgen Inc.'s shareholders as part of Gyre's acquisition of Cullgen completed on May 07, 2026. The registration does not aim to raise additional funds for Gyre.
As of June 24, 2026, GNI Group’s effective holding ratio in Gyre remains approximately 70% without changes to its investment strategy. The company expects no significant impact on its consolidated performance due to this registration process. On June 23, 2026, Gyre Therapeutics, Inc.
Submitted its Form S-3 registration statement identified as 1,140,99.
🟡 Confidence: Standard AI-translated content.